18 / 24
Second-Line Oxaliplatin-Based Regimens
Conflicting Results From Phase III Trials
CONKO-003
1
PANCREOX
2
Pts [N = 268]
PD on Gem Therapy [n = 160]
Previous Gem Therapy [n = 108]
Treatment
OFF
(n = 76)
5-FU/LV
(n = 84)
mFOLFOX6
(n = 54)
5-FU/LV
(n = 54)
OS, median
5.9 months
3.3 months 6.1 months
9.9 months
HR 0.66 (95% CI, 0.48-0.91)
P
= .01
HR 1.78 (95% CI, 1.08-2.93)
P
= .02
PFS, median
2.9 months
2.0 months 3.1 months
2.9 months
HR 0.68 (95% CI, 0.50-0.94)
P
= .02
HR 1.00 (95% CI, 0.66-1.53)
P
= .99
1. Oettle H, et al.
J Clin Oncol
. 2014;32(23):2423-2429. 2. Gill S, et al.
J Clin Oncol
. 2016;34(32):3914-3920.
PD, progressive disease